Go or no go? A delayed decision on Evrenzo
March will see big US decisions for Evrenzo and ide-cel, while tanezumab goes in front of an advisory committee.
A Spac makes it happen for 4D Pharma
The boom in blank-cheque companies could offer small UK developers a new route to a US stock market listing.
Despite Imfinzi, US accelerated approvals surge
More and more drugs are being approved conditionally on flimsy data, and Imfinzi is just the second to be pulled after failing a confirmatory trial.
Lynparza’s Olympia win could broaden breast cancer use
The Parp inhibitor registers an unexpected clinical win in the adjuvant setting, but more convincing data might still be needed.
Can we freeze them? Yes we can, says Nkarta
The company is now in the clinic, claiming to have cleared one of the biggest hurdles blocking development of an NK cell therapy.
Asco-GU – Clear blue water between Keytruda and kidney cancer rivals
Merck & Co/Eisai’s Clear study results look better than Bristol/Exelixis’s Checkmate-9ER, but the big loser could be Pfizer.
